The present study was, therefore, designed to answer a pertinent research question for physicians, healthcare payers and people with type 2 diabetes in the UK and to elucidate the relative cost-effectiveness of several highly efficacious GLP-1 receptor agonist therapies. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.